LEXINGTON, Mass., Aug. 4,
2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an
immuno-oncology company with an extensive pipeline of checkpoint
antibodies, cell therapy, adjuvants, and vaccines designed to
activate immune response to cancers and
infections, announced today that Dr. Jennifer Buell, President and COO of Agenus will
present on Targeting Myeloid Cells in the Tumor Microenvironment at
the upcoming William Blair Biotech Focus Conference 2020.
Date: Tuesday, August 4,
2020
Webcast Info: http://wsw.com/webcast/blair57/p1/
Title: Targeting Myeloid Cells in Tumor
Microenvironment
Time: 11:00AM – 12:00 PM
Keynote Speaker:
Miriam
Merad, M.D., Ph.D., - Chair Professor in Cancer Immunology
and Director of the Precision Immunology Institute Mount Sinai
School of Medicine
Presentations:
Agenus Inc.
Jennifer Buell, Ph.D. – President and Chief
Operating Officer
Codiak Biosciences
Douglas
Williams, Ph.D. - President and Chief Executive Officer
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its AgenTus
Therapeutics subsidiary), and proprietary cancer vaccine platforms.
The Company is equipped with a suite of antibody discovery
platforms and a state-of-the-art GMP manufacturing facility with
the capacity to support clinical programs. Agenus is headquartered
in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and twitter.
Contact:
Agenus Inc.
Jennifer
Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/agenus-to-present-on-targeting-myeloid-cells-in-tumor-microenvironment-at-the-william-blair-biotech-focus-2020-conference-301105604.html
SOURCE Agenus Inc.